EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Dexmedetomidine effects on metabolic rate over 5 days in humans

Clifton W Callaway iD, Alexandra J Weissman, Katharyn L Flickinger iD, Victor Wu, Jenna Monteleone, Ryann DeMaio, Mara Hierro, Daniel Neofes, Omarf Ortega-Reyes, Tao Sheng, Marianna Salinas, Paul Lerro und 6 weitere

PLOS One · 2026

DOI: 10.1371/journal.pone.0359711 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2026. Verfasst von Clifton W Callaway und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Dexmedetomidine, Energy Metabolism, Adrenergic alpha-2 Receptor Agonists, Hypnotics and Sedatives. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Aeronautics and Space Administration, NIH Office of the Director.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The alpha-2-adrenergic agonist drug dexmedetomidine induces sleep-like sedation and reduces global metabolic rate. Drug-induced metabolic suppression sustained over days in humans could be a strategy for reducing energy expenditure (EE), oxygen consumption (VO 2 ), and carbon dioxide production (VCO 2 ) during prolonged rescue or austere conditions with limited life-support. We tested the feasibility of reducing EE, VO 2 and VCO 2 measured with intermittent indirect calorimetry using subcutaneous infusion of dexmedetomidine 1 µg/kg/hour for 18 hours per day over five days in healthy adults. Five participants received multiple days of dexmedetomidine in a laboratory setting, and five separate participants received placebo for one or five days. Relative to resting metabolic rate, dexmedetomidine infusion reduced VO 2 (effects, 95%CI, at 6-hour time epoch: −0.084 L/min, −0.145 to −0.023), VCO 2 (−0.067 L/min, −0.130 to −0.005) and EE (−577 kcal/day, −1016 to −137). Relative to placebo, dexmedetomidine produced light sedation (Richmond Agitation Sedation Score: −1.25; 95%CI −1.70 to −0.80 relative to placebo), with lower heart rate (−15 beats/minute; 95%CI −23 to −7) and core body temperature (−1.3ºC; 95%CI −1.7 to −0.8). Dexmedetomidine effects on all physiological variables decreased over time and were absent after day 2. Maximum and minimum plasma drug levels did not change over days. Participants reported rebound anxiety and insomnia after the study. Administering a sedating level of dexmedetomidine that reduces VO 2 , VCO 2 , and EE for 2 days was feasible in healthy adults. However, tolerance to drug effects develops by 3 days, which is a critical limitation for long-term use of this drug regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineEnergy MetabolismAdrenergic alpha-2 Receptor AgonistsHypnotics and SedativesBasal MetabolismHumansOxygen ConsumptionAdultFemaleMaleCarbon DioxideYoung AdultCalorimetry, Indirect

Substanzen

DexmedetomidineCarbon DioxideAdrenergic alpha-2 Receptor AgonistsHypnotics and Sedatives

Autor:innen und Institutionen

  • Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
  • Department of Health and Human Development, University of Pittsburgh School of Education, Pittsburgh, Pennsylvania, United States of America.
  • Department of Nutrition, University of Rhode Island College of Health Sciences, Kingston, Rhode Island, United States of America.
  • Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
  • Center for Clinical Pharmaceutical Sciences, Department of Pharmacy, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, United States of Americaand Therapeutics, University of Pittsburgh School of Ph…

ORCID-Profile: Clifton W Callaway, Katharyn L Flickinger, Benjamin D H Gordon, Marie Mortreux

Förderung

  • NIH HHS
  • National Aeronautics and Space Administration
  • NIH Office of the Director

Zitieren

APA

Callaway, C. W., Weissman, A. J., Flickinger, K. L., Wu, V., Monteleone, J., DeMaio, R., Hierro, M., Neofes, D., Ortega-Reyes, O., Sheng, T., Salinas, M., Lerro, P., Guyette, F. X., Gordon, B. D. H., Mortreux, M., Melanson, K., Buysee, D. J., & Empey, P. E. (2026). Dexmedetomidine effects on metabolic rate over 5 days in humans. PLOS One. https://doi.org/10.1371/journal.pone.0359711

Vancouver

Callaway CW, Weissman AJ, Flickinger KL, Wu V, Monteleone J, DeMaio R, et al. Dexmedetomidine effects on metabolic rate over 5 days in humans. PLOS One. 2026. doi:10.1371/journal.pone.0359711

BibTeX
@article{Callaway2026,
  author = {Callaway, Clifton W and Weissman, Alexandra J and Flickinger, Katharyn L and Wu, Victor and Monteleone, Jenna and DeMaio, Ryann and Hierro, Mara and Neofes, Daniel and Ortega-Reyes, Omarf and Sheng, Tao and Salinas, Marianna and Lerro, Paul and Guyette, Francis X and Gordon, Benjamin D H and Mortreux, Marie and Melanson, Kathleen and Buysee, Daniel J and Empey, Philip E},
  title = {Dexmedetomidine effects on metabolic rate over 5 days in humans},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0359711}
}
Kostenlos starten →